• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Admissions for posttransplant lymphoproliferative disorder: a 9-year longitudinal analysis of the National (Nationwide) Inpatient Sample.移植后淋巴细胞增生性疾病的住院情况:对国家(全国)住院患者样本的9年纵向分析。
Proc (Bayl Univ Med Cent). 2024 Jul 11;37(5):804-812. doi: 10.1080/08998280.2024.2375688. eCollection 2024.
2
Gender Disparities in Hospitalization Outcomes and Healthcare Utilization Among Patients with Systemic Lupus Erythematosus in the United States.美国系统性红斑狼疮患者住院治疗结果及医疗服务利用方面的性别差异
Cureus. 2023 Jul 1;15(7):e41254. doi: 10.7759/cureus.41254. eCollection 2023 Jul.
3
Posttransplant lymphoproliferative disorders in kidney transplant recipients: an Iranian multicenter experience.肾移植受者的移植后淋巴增殖性疾病:一项伊朗多中心研究经验。
Iran J Kidney Dis. 2008 Oct;2(4):227-33.
4
Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).小儿肾移植术后淋巴组织增生性疾病(PTLD)的危险因素:北美小儿肾移植协作研究(NAPRTCS)报告
Transplantation. 2001 Apr 27;71(8):1065-8. doi: 10.1097/00007890-200104270-00010.
5
Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis.不列颠哥伦比亚省接受肾移植的成年人中的移植后淋巴细胞增生性疾病:一项回顾性队列分析。
Can J Kidney Health Dis. 2018 Apr 1;5:2054358118760831. doi: 10.1177/2054358118760831. eCollection 2018.
6
Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.爱尔兰肾移植受者的移植后淋巴细胞增生性疾病:一项全国性观察研究的见解
Transplantation. 2017 Mar;101(3):657-663. doi: 10.1097/TP.0000000000001201.
7
Discharge dispositions, complications, and costs of hospitalization in spinal cord tumor surgery: analysis of data from the United States Nationwide Inpatient Sample, 2003-2010.脊髓肿瘤手术住院患者的出院转归、并发症和住院费用:对 2003-2010 年美国全国住院患者样本数据的分析。
J Neurosurg Spine. 2014 Feb;20(2):125-41. doi: 10.3171/2013.9.SPINE13274. Epub 2013 Nov 29.
8
Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.成人肾移植后淋巴组织增生性疾病:流行病学及登记报告与基于理赔诊断的比较。
Am J Kidney Dis. 2011 Dec;58(6):971-80. doi: 10.1053/j.ajkd.2011.07.015. Epub 2011 Sep 17.
9
Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience.肝移植后淋巴增殖性疾病:20年经验
Ann Surg. 2002 Oct;236(4):429-36; discussion 436-7. doi: 10.1097/00000658-200210000-00005.
10
Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients.移植后淋巴细胞增生性疾病:肺移植受者的发病率、表现及对治疗的反应
Chest. 2003 Oct;124(4):1242-9. doi: 10.1378/chest.124.4.1242.

本文引用的文献

1
Disparities in mortality among acute myeloid leukemia-related hospitalizations.急性髓系白血病相关住院患者的死亡率差异。
Cancer Med. 2023 Feb;12(3):3387-3394. doi: 10.1002/cam4.5084. Epub 2022 Aug 4.
2
Decreasing length of stay and inpatient mortality associated with pancreatic cancer hospitalizations: A United States national survey from 2008 to 2017.与胰腺癌住院相关的住院时间和住院死亡率的降低:2008 年至 2017 年美国全国调查。
Pancreatology. 2022 Jun;22(5):590-597. doi: 10.1016/j.pan.2022.04.008. Epub 2022 Apr 19.
3
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.L-MIND 研究中 tafasitamab(MOR208)联合来那度胺治疗复发/难治性弥漫性大 B 细胞淋巴瘤患者的长期结果。
Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958.
4
Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status.医疗保险资格患者肾移植后移植后淋巴组织增生性疾病的成本负担按生存状况划分。
J Med Econ. 2021 Jan-Dec;24(1):620-627. doi: 10.1080/13696998.2021.1915793.
5
Etiology and management of hypertension in patients with cancer.癌症患者高血压的病因及管理
Cardiooncology. 2021 Apr 6;7(1):14. doi: 10.1186/s40959-021-00101-2.
6
Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.异基因造血干细胞移植后 1 年内发生移植后淋巴组织增生性疾病患者的医疗资源利用和成本的回顾性数据库分析。
J Med Econ. 2020 Oct;23(10):1159-1167. doi: 10.1080/13696998.2020.1793765. Epub 2020 Jul 22.
7
Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.移植后淋巴细胞增生性疾病:当前概念与未来治疗方法
World J Transplant. 2020 Feb 28;10(2):29-46. doi: 10.5500/wjt.v10.i2.29.
8
Inpatient burden of gastric cancer in the United States.美国胃癌的住院负担。
Ann Transl Med. 2019 Dec;7(23):772. doi: 10.21037/atm.2019.11.54.
9
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.移植后淋巴组织增生性疾病、爱泼斯坦-巴尔病毒感染和实体器官移植中的疾病:美国移植感染病学会实践社区指南。
Clin Transplant. 2019 Sep;33(9):e13652. doi: 10.1111/ctr.13652. Epub 2019 Jul 23.
10
Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients.移植后淋巴细胞增生性疾病(PTLD):141例患者的单机构经验
Exp Hematol Oncol. 2017 Sep 29;6:26. doi: 10.1186/s40164-017-0087-0. eCollection 2017.

移植后淋巴细胞增生性疾病的住院情况:对国家(全国)住院患者样本的9年纵向分析。

Admissions for posttransplant lymphoproliferative disorder: a 9-year longitudinal analysis of the National (Nationwide) Inpatient Sample.

作者信息

El-Amir Zain, Jamil Abdur, Solanki Dhanshree, Mansuri Uvesh, Mathew Midhun, Singh Jagmeet, Aslam Shehroz, Akram Hamza, Mandal Shobha, Kichloo Asim

机构信息

Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.

Division of Internal Medicine, Samaritan Medical Center, Watertown, New York, USA.

出版信息

Proc (Bayl Univ Med Cent). 2024 Jul 11;37(5):804-812. doi: 10.1080/08998280.2024.2375688. eCollection 2024.

DOI:10.1080/08998280.2024.2375688
PMID:39165820
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11332645/
Abstract

BACKGROUND

Posttransplant lymphoproliferative disorder (PTLD), a term that encompasses a wide array of malignancies that occur after transplant, can be one of the most devastating transplant complications. While there have been major advancements in care, especially after the landmark PTLD-1 trial in 2012, there is a paucity of information on hospitalizations for PTLD and the changes in hospitalizations over time.

METHODS

This retrospective cohort study used the National Inpatient Sample to identify hospitalizations for PTLD that occurred between 2009 and 2018. We extracted data for hospitalizations with a primary or secondary diagnosis of PTLD and examined a range of variables, including age, gender, race, hospital type, hospital location, and disposition status. We also collected data on hospital region, median household income, insurance status, and bed size.

RESULTS

There was a statistically significant increase in the number of hospitalizations from 2009 to 2019 and an increasing rate of hospitalizations over the study period. Hypertension, electrolyte imbalances, renal failure, and anemia were among the most common comorbidities. We found an increased mortality rate, but this was not statistically significant.

CONCLUSION

Our study provides insight into the changes in hospitalizations for PTLD over nearly a decade, showing an increase in hospitalizations and reports of comorbidities.

摘要

背景

移植后淋巴细胞增生性疾病(PTLD)是一个涵盖移植后发生的多种恶性肿瘤的术语,可能是最具破坏性的移植并发症之一。尽管在治疗方面取得了重大进展,尤其是在2012年具有里程碑意义的PTLD-1试验之后,但关于PTLD住院情况以及住院情况随时间的变化的信息却很少。

方法

这项回顾性队列研究使用国家住院样本确定2009年至2018年期间发生的PTLD住院情况。我们提取了主要或次要诊断为PTLD的住院数据,并检查了一系列变量,包括年龄、性别、种族、医院类型、医院位置和出院状态。我们还收集了医院所在地区、家庭收入中位数、保险状况和床位规模的数据。

结果

从2009年到2019年,住院人数有统计学意义的增加,并且在研究期间住院率不断上升。高血压、电解质失衡、肾衰竭和贫血是最常见的合并症。我们发现死亡率有所上升,但这在统计学上并不显著。

结论

我们的研究深入了解了近十年来PTLD住院情况的变化,显示住院人数和合并症报告有所增加。